Your browser is no longer supported. Please, upgrade your browser.
LLY Eli Lilly and Company daily Stock Chart
Eli Lilly and Company
IndexS&P 500 P/E41.19 EPS (ttm)2.10 Insider Own11.30% Shs Outstand1.09B Perf Week0.73%
Market Cap94.63B Forward P/E18.67 EPS next Y4.63 Insider Trans-1.33% Shs Float1.09B Perf Month4.86%
Income2.22B PEG3.50 EPS next Q1.07 Inst Own78.80% Short Float1.03% Perf Quarter4.92%
Sales22.47B P/S4.21 EPS this Y14.10% Inst Trans1.04% Short Ratio3.40 Perf Half Y5.64%
Book/sh14.14 P/B6.12 EPS next Y10.10% ROA5.50% Target Price91.55 Perf Year27.83%
Cash/sh6.35 P/C13.63 EPS next 5Y11.78% ROE15.60% 52W Range69.66 - 89.09 Perf YTD17.61%
Dividend2.08 P/FCF24.92 EPS past 5Y-8.00% ROI11.60% 52W High-2.91% Beta0.34
Dividend %2.40% Quick Ratio1.00 Sales past 5Y-2.70% Gross Margin73.70% 52W Low24.17% ATR1.26
Employees41975 Current Ratio1.40 Sales Q/Q9.00% Oper. Margin12.40% RSI (14)57.18 Volatility1.77% 1.45%
OptionableYes Debt/Eq0.90 EPS Q/Q-28.30% Profit Margin9.90% Rel Volume1.34 Prev Close86.50
ShortableYes LT Debt/Eq0.67 EarningsJan 23 BMO Payout98.20% Avg Volume3.31M Price86.50
Recom2.30 SMA201.61% SMA501.88% SMA2004.34% Volume0 Change0.00%
Oct-10-17Downgrade Credit Suisse Outperform → Neutral
Jul-26-17Downgrade Leerink Partners Outperform → Mkt Perform
Apr-27-17Downgrade Argus Buy → Hold
Apr-17-17Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-07-17Reiterated Barclays Overweight $85 → $90
Mar-20-17Reiterated UBS Neutral $70 → $85
Dec-16-16Upgrade Morgan Stanley Equal-Weight → Overweight
Sep-27-16Upgrade Goldman Neutral → Buy
Sep-08-16Upgrade JP Morgan Neutral → Overweight
May-02-16Reiterated Leerink Partners Outperform $96 → $101
Apr-06-16Initiated Societe Generale Hold $78
Dec-28-15Reiterated Leerink Partners Outperform $93 → $95
Dec-07-15Upgrade Deutsche Bank Hold → Buy $85 → $99
Dec-01-15Upgrade Barclays Equal Weight → Overweight $75 → $95
Nov-12-15Reiterated Leerink Partners Outperform $90 → $93
Oct-09-15Upgrade Credit Suisse Neutral → Outperform
Sep-21-15Reiterated JP Morgan Neutral $83 → $90
Sep-18-15Reiterated Jefferies Buy $105 → $115
Sep-18-15Reiterated BofA/Merrill Buy $101 → $108
Aug-27-15Initiated Berenberg Buy
Dec-15-17 07:50AM  Pharma Stock Roundup: Teva Announces Major Job Cuts, Lilly Provides 2018 Outlook Zacks
Dec-14-17 12:30PM  Rimidi and Lilly Collaborate to Personalize Solutions for People Using Insulin PR Newswire
10:28AM  Bristol-Myers Squibbs Valuation in December 2017 Market Realist
10:22AM  Lilly Issues Guidance for 2018, New Drugs to Drive Top Line Zacks
09:51AM  10 Biggest Antidepressant Drug Companies In 2017 Insider Monkey
Dec-13-17 10:05AM  Eli Lilly: Updated Guidance Is a Shot in the Arm
08:45AM  Lilly's 2018 forecast beats on strength of new drugs Reuters
08:15AM  Stocks making the biggest moves premarket: HON, LLY, AMGN, TM, HD & more CNBC
06:55AM  Lilly forecasts 2018 profit largely above estimates Reuters
06:45AM  Lilly Announces 2018 Financial Guidance and Enhances Outlook Through 2020 PR Newswire
Dec-12-17 10:30AM  What Analysts Recommend for Eli Lilly in December 2017 Market Realist
09:21AM  Sanofi Wins FDA Approval for Biosimilar of Lilly's Humalog Zacks
09:00AM  How Is Olumiant Positioned after 3Q17? Market Realist
07:30AM  How Eli Lillys Animal Health Products Performed in 3Q17 Market Realist
Dec-11-17 03:38PM  Eli Lilly raises dividend by 8% CNBC Videos
03:36PM  Eli Lilly hikes dividend by 8% MarketWatch
03:30PM  Lilly Announces 8 Percent Dividend Increase PR Newswire
02:12PM  Lilly Reports Mixed Results from Late-Stage Cyramza Study Zacks
02:04PM  FDA OKs Sanofi's follow-on biologic of Lilly's diabetes drug Humalog Reuters
01:13PM  FDA clears Sanofi's follow-on diabetes biologic of Lilly's Humalog Reuters
10:30AM  An Update on Eli Lillys Oncology Drugs: Alimta, Erbitux, and Gemzar Market Realist
09:00AM  How Is Eli Lillys Neuroscience Portfolio Positioned after 3Q17? Market Realist
07:31AM  How Has Eli Lillys Cyramza Performed Market Realist
06:45AM  FDA Accepts Biologics License Application (BLA) to Review Galcanezumab for the Prevention of Migraine in Adults PR Newswire
06:30AM  Kimberly Blackwell, M.D., to become Vice President of Early Phase Development and Immuno-oncology at Lilly Oncology PR Newswire
Dec-08-17 06:27PM  Lilly's stomach cancer drug meets main goal, but fails to improve survival rate Reuters
06:17PM  Lilly's Cyramza meets main goal in gastric cancer study Reuters
05:00PM  Lilly Reports Top-Line Results from CYRAMZA® (ramucirumab) Phase 3 Study in First-Line Advanced Gastric Cancer PR Newswire
10:31AM  How Is Eli Lillys Taltz Positioned Now? Market Realist
09:02AM  How Eli Lillys Trajenta, Trulicity, and Basaglar Are Performing Market Realist
07:40AM  Pharma Stock Roundup: FDA Nod for NVO's Ozempic, Second Indication for Lilly's Taltz Zacks
07:32AM  How Eli Lillys Endocrinology Drugs Are Performing Market Realist
Dec-07-17 05:50PM  How Eli Lillys Forteo and Jardiance Are Performing Market Realist
04:20PM  How Eli Lillys Cardiovascular Portfolio Performed Market Realist
02:45PM  How Did Eli Lilly Perform in 3Q17? Market Realist
07:33AM  With -8.7% Earnings Drop Lately, Did Eli Lilly and Company (LLY) Underperform Its Industry? Simply Wall St.
Dec-06-17 08:01AM  See what the IHS Markit Score report has to say about Eli Lilly And Co. Markit
Dec-05-17 04:35PM  FDA approves diabetes drug that also helps with weight loss Associated Press
09:00AM  Lilly Initiates Clinical Trial to Evaluate the Functionality and Safety of its Automated Insulin Delivery System PR Newswire
08:01AM  See what the IHS Markit Score report has to say about Eli Lilly And Co. Markit
07:50AM  Blog Exposure - FDA Approves Eli Lilly's Taltz(R) for the Treatment of Active PsA ACCESSWIRE
07:30AM  What Analysts Recommend for Pfizer in November 2017 Market Realist
Dec-04-17 09:11AM  Lilly's (LLY) Taltz Gets Approval for Label Expansion in US Zacks
08:01AM  See what the IHS Markit Score report has to say about Eli Lilly And Co. Markit
07:30AM  Eli Lilly on the Street: Analyst Recommendations in November Market Realist
Dec-01-17 05:01PM  Lilly's Taltz® (ixekizumab) Receives U.S. FDA Approval for the Treatment of Active Psoriatic Arthritis PR Newswire
10:31AM  Understanding Eli Lillys Estimates after 3Q17 Market Realist
09:01AM  Understanding Eli Lillys Valuation This November Market Realist
07:31AM  Reading Eli Lillys Latest Developments after 3Q17 Market Realist
03:56AM  Dividend Century Aristocrats: Ranking 5 Buys Today Harvest Exchange
Nov-30-17 01:38PM  Jim Cramer Reveals His Top Takeover Targets for 2018
10:31AM  Inside Eli Lillys Animal Health Business in 3Q17 Market Realist
09:01AM  Eli Lillys Cialis and Other Cardiovascular Products in 3Q17 Market Realist
07:33AM  Behind Eli Lillys Cymbalta and Other Neuroscience Products in 3Q17 Market Realist
Nov-29-17 03:16PM  Trump health pick parries questions on drug cost, health law Associated Press
03:08PM  [$$] HHS Nominee Says He Has Prescription to Lower Drug Costs The Wall Street Journal
10:33AM  Behind Eli Lillys Alimta and Other Oncology Products in 3Q17 Market Realist
09:03AM  Behind Eli Lillys Humalog and Other Endocrine Products in 3Q17 Market Realist
07:34AM  Eli Lillys New Pharmaceutical Products in 3Q17 Market Realist
Nov-28-17 05:15PM  Nektar Therapeutics Raised Its Revenue Guidance for 2017 Market Realist
04:55PM  How Eli Lillys Business Segments Performed in 3Q17 Market Realist
03:42PM  Analyst Recommendations for Nektar Therapeutics in November 2017 Market Realist
03:23PM  Inside Eli Lillys Revenue Trends in 3Q17 Market Realist
01:29PM  In Trump health secretary pick, Dems have questions but hope Associated Press
07:20AM  Eli Lilly & Co. breached its 50 day moving average in a Bullish Manner : LLY-US : November 28, 2017 Capital Cube
06:35AM  Learn From My Portfolio Mistakes: Cramer's 'Mad Money' Recap (Monday 11/27/17)
Nov-27-17 02:34PM  ETFs with exposure to Eli Lilly & Co. : November 27, 2017 Capital Cube
09:58AM  Better Buy: Eli Lilly and Co. vs. Merck & Co., Inc. Motley Fool
Nov-24-17 01:30PM  Whats Johnson & Johnsons Valuation? Market Realist
Nov-23-17 11:58PM  Eli Lilly Bets Big on Insulin-Delivery Devices The Wall Street Journal
07:30AM  Analysts Recommendations for Merck in November 2017 Market Realist
Nov-22-17 04:19PM  Dexcom now working with Fitbit to help with diabetes management Fox Business Videos
10:39AM  Lilly Inks Deal to Include Dexcom Products in Diabetes System Zacks
09:13AM  DexCom-Lily Partnership to Boost CGM Platform, Customer Base Zacks
Nov-21-17 01:55PM  United Therapeutics gets much-needed reprieve with drug patent American City Business Journals
10:33AM  Dexcom Announces Development Agreement with Lilly to Integrate Dexcom CGM into Connected Diabetes Ecosystem Business Wire
10:08AM  United Therapeutics PAH Drug's Exclusivity Period Extended Zacks
Nov-20-17 03:58PM  Health nominee reaped big earnings from drug industry tenure Associated Press
10:30AM  Lilly Confirms Date and Conference Call for 2018 Financial Guidance Announcement PR Newswire
09:33AM  Celldex (CLDX) Initiates Phase II Study on Cancer Candidate Zacks
Nov-17-17 03:45PM  Lilly to Participate in Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference PR Newswire
Nov-16-17 11:26AM  AstraZenecas Valuation after 3Q17 Earnings Market Realist
08:00AM  See what the IHS Markit Score report has to say about Eli Lilly And Co. Markit
Nov-15-17 07:22PM  [$$] Two Lawsuits Hit Express Scripts Unit on Pricing
02:56PM  9 Must-Own Stocks That Have Paid Over a Century of Dividends InvestorPlace
Nov-14-17 09:00PM  Donald Trump's Nominee for HHS Secretary Causes a Tumble in Biotech Stocks Motley Fool
03:55PM  How Novartiss Cosentyx Is Positioned after 3Q17 Market Realist
02:35PM  Understanding Sanofis Revenues by Segment in 3Q17 Market Realist
01:14PM  Eli Lilly & Co. : LLY-US: Dividend Analysis : November 15th, 2017 (record date) : By the numbers : November 14, 2017 Capital Cube
09:29AM  Novo Nordisk & 4 Other Pharma Stocks in Focus on World Diabetes Day Zacks
08:01AM  See what the IHS Markit Score report has to say about Eli Lilly And Co. Markit
12:33AM  [$$] Oh, No, a Pharma Exec The Wall Street Journal
12:32AM  [$$] HHS Nominee Oversaw Big Drug Price Increases at Lilly The Wall Street Journal
Nov-13-17 06:45PM  Jardiance® reduced risk of cardiovascular death in adults with type 2 diabetes and peripheral artery disease PR Newswire
06:12PM  [$$] Oh, No, a Pharma Exec The Wall Street Journal
06:01PM  Cost of diabetes epidemic reaches $850 billion a year Reuters
03:15PM  [$$] HHS Nominee Oversaw Big Drug Price Increases at Lilly The Wall Street Journal
02:00PM  Lilly Appoints Philip Johnson to Senior Vice President and Treasurer PR Newswire
12:42PM  ETFs with exposure to Eli Lilly & Co. : November 13, 2017 Capital Cube
11:39AM  President Trump Nominates Alex Azar for HHS Secretary
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. It operates through two segments, Human Pharmaceutical Products and Animal Health Products. The company offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency. It also provides neuroscience products for the treatment of depressive disorders, diabetic peripheral neuropathic pain, anxiety disorders, fibromyalgia, and chronic musculoskeletal pain; schizophrenia; attention-deficit hyperactivity disorders; depressive, obsessive-compulsive, bulimia nervosa, and panic disorders; and positron emission tomography imaging of beta-amyloid neurotic plaques in adult brains. In addition, the company offers products to treat non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and cardiovascular products to treat erectile dysfunction and benign prostatic hyperplasia; and migraine headaches. Further, it provides animal health products, such as cattle feed additives; protein supplements for cows; leanness and performance enhancers for swine and cattle; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; anticoccidial agents for poultry; and chewable tablets that kill fleas and prevent flea infestations, and heartworm diseases, as well as controls intestinal parasite infections. Additionally, the company offers vaccinev to prevent Lyme disease, bronchial infections, rabies, and various infectious diseases in dogs, cats, and horses. It has collaboration agreements with Daiichi Sankyo Co., Ltd., Incyte Corporation, Pfizer Inc., AstraZeneca, William Sansum Diabetes Center, Purdue University, and Nektar Therapeutics. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LILLY ENDOWMENT INC10% OwnerDec 13Sale88.20200,00017,639,176123,075,804Dec 14 11:26 AM
Simmons Jeffrey NSVP&Pres. Elanco Animal HealthDec 11Sale86.4612,5001,080,750124,522Dec 13 03:01 PM
Zulueta Alfonso GSVP & President, Lilly Int'lDec 04Sale86.003,532303,75240,048Dec 05 05:35 PM
Mahony SusanSVP & Pres., Lilly OncologyDec 04Sale86.1836,5853,152,89554,885Dec 05 05:32 PM
Zakrowski Donald AChief Accounting OfficerDec 03Option Exercise0.003,28104,167Dec 05 05:48 PM
Fry Stephen FSVP, HR & DiversityDec 03Option Exercise0.007,557086,501Dec 05 05:46 PM
Ricks David APresident & CEODec 03Option Exercise0.005,4960110,059Dec 05 05:43 PM
Zulueta Alfonso GSVP & President, Lilly Int'lNov 10Sale83.672,003167,59143,580Nov 13 12:55 PM
LILLY ENDOWMENT INC10% OwnerOct 04Sale86.81205,00017,795,025123,275,804Oct 05 02:56 PM
LILLY ENDOWMENT INC10% OwnerSep 29Sale85.14195,00016,602,601123,480,804Oct 02 03:39 PM
LILLY ENDOWMENT INC10% OwnerSep 15Sale82.53190,00015,679,772123,675,804Sep 18 03:42 PM
LILLY ENDOWMENT INC10% OwnerAug 31Sale81.06180,00014,590,080123,865,804Sep 01 01:45 PM
LILLY ENDOWMENT INC10% OwnerJul 31Sale83.09220,00018,279,478124,045,804Aug 01 10:55 AM
LILLY ENDOWMENT INC10% OwnerJun 22Sale84.43210,00017,730,720124,265,804Jun 23 10:16 AM
LILLY ENDOWMENT INC10% OwnerJun 20Sale83.05215,00017,855,363124,475,804Jun 21 11:24 AM
Barnes Melissa SChief Eth/Cmpl Ofcr & SVP, ERMJun 12Sale80.781,900153,48214,041Jun 13 04:10 PM
Harrington Michael JSenior VP and General CounselJun 09Sale79.9722,8331,825,95562,056Jun 09 04:15 PM
Conterno Enrique ASVP&Pres, LillyDiab & LillyUSAMay 04Sale82.7625,0002,069,000114,217May 08 03:44 PM
LILLY ENDOWMENT INC10% OwnerMar 30Sale84.67210,00017,781,540124,690,804Mar 31 11:11 AM
LILLY ENDOWMENT INC10% OwnerFeb 17Sale80.27230,00018,462,790125,125,804Feb 21 03:45 PM
Zulueta Alfonso GSVP& Pres., Emerging MarketsFeb 06Sale77.6615,0001,164,90045,583Feb 08 10:02 AM
Rice Derica WEVP-Global Services and CFOFeb 03Sale77.473,892301,51338,292Feb 03 05:20 PM
Rice Derica WEVP-Global Services and CFOFeb 02Sale76.977,270559,57242,184Feb 03 05:20 PM
Zakrowski Donald AChief Accounting OfficerFeb 02Sale77.522,000155,040886Feb 03 03:22 PM
Barnes Melissa SChief Eth/Cmpl Ofcr & SVP, ERMFeb 01Option Exercise0.003,073017,361Feb 03 03:24 PM
Zulueta Alfonso GSVP& Pres., Emerging MarketsFeb 01Option Exercise0.006,659063,710Feb 03 03:20 PM
Walsh Fionnuala MSVP, Global QualityFeb 01Option Exercise0.004,610069,309Feb 03 03:18 PM
Simmons Jeffrey NSVP&Pres. Elanco Animal HealthFeb 01Option Exercise0.0010,2440141,753Feb 03 03:16 PM
Ricks David APresident & CEOFeb 01Option Exercise0.0010,2440109,400Feb 03 03:13 PM
Peterson Barton RSr. VP, Corp. Affairs & Comm.Feb 01Option Exercise0.005,6340110,958Feb 03 03:11 PM
Mahony SusanSVP & Pres., Lilly OncologyFeb 01Option Exercise0.009,732096,040Feb 03 03:08 PM
Lundberg Jan MEVP,Science&Tech and Pres. LRLFeb 01Option Exercise0.0015,3660162,368Feb 03 03:04 PM
LECHLEITER JOHN CDirectorFeb 01Option Exercise0.0046,0970855,987Feb 03 03:01 PM
Harrington Michael JSenior VP and General CounselFeb 01Option Exercise0.009,732089,432Feb 03 02:58 PM
Fry Stephen FSVP, HR & DiversityFeb 01Option Exercise0.007,683082,552Feb 03 02:53 PM
Crowe Maria APresident, Mfg. OperationsFeb 01Option Exercise0.008,1950117,313Feb 03 02:41 PM
Conterno Enrique ASr. VP & Pres., Lilly DiabetesFeb 01Option Exercise0.0010,2440144,027Feb 03 02:35 PM
Rice Derica WEVP-Global Services and CFOFeb 01Option Exercise0.0019,463058,443Feb 03 05:20 PM
LILLY ENDOWMENT INC10% OwnerFeb 01Sale77.35220,00017,016,840125,355,804Feb 02 03:38 PM
HOOVER R DAVIDDirectorDec 16Buy71.8550035,9251,500Dec 19 02:15 PM
TAI JACKSON PDirectorDec 16Buy72.641,37599,88048,815Dec 19 02:45 PM
Zakrowski Donald AChief Accounting OfficerDec 16Sale72.131,00072,130300Dec 19 02:48 PM
Mahony SusanSVP & Pres., Lilly OncologyDec 16Sale72.681,14983,50911,479Dec 19 02:40 PM
Mahony SusanSVP & Pres., Lilly OncologyDec 16Sale72.6519,0931,387,10667,802Dec 19 02:40 PM
Barnes Melissa SChief Eth/Cmpl Ofcr & SVP, ERMDec 16Sale82.232,093172,1078,169Dec 19 02:10 PM
LILLY ENDOWMENT INC10% OwnerDec 16Sale72.59200,00014,518,477125,575,804Dec 19 05:02 PM